Optimum Investment Advisors decreased its holdings in shares of Davita Inc (NYSE:DVA) by 10.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 3,260 shares of the company’s stock after selling 380 shares during the period. Optimum Investment Advisors’ holdings in Davita were worth $183,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. Barings LLC bought a new stake in shares of Davita during the 1st quarter valued at $1,568,000. GHP Investment Advisors Inc. raised its position in shares of Davita by 1.5% during the 1st quarter. GHP Investment Advisors Inc. now owns 30,265 shares of the company’s stock valued at $1,643,000 after acquiring an additional 460 shares during the last quarter. Clearbridge Investments LLC raised its position in shares of Davita by 63.5% during the 1st quarter. Clearbridge Investments LLC now owns 798 shares of the company’s stock valued at $43,000 after acquiring an additional 310 shares during the last quarter. Northstar Group Inc. raised its position in shares of Davita by 33.2% during the 2nd quarter. Northstar Group Inc. now owns 9,082 shares of the company’s stock valued at $511,000 after acquiring an additional 2,266 shares during the last quarter. Finally, Securian Asset Management Inc raised its position in shares of Davita by 1.7% during the 1st quarter. Securian Asset Management Inc now owns 13,178 shares of the company’s stock valued at $715,000 after acquiring an additional 217 shares during the last quarter. Institutional investors own 87.54% of the company’s stock.
Several brokerages have commented on DVA. William Blair reiterated a “buy” rating on shares of Davita in a research report on Thursday, June 20th. Deutsche Bank lowered their price objective on shares of Davita from $68.00 to $66.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. Robert W. Baird cut shares of Davita from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $70.00 to $65.00 in a research report on Friday, July 26th. ValuEngine upgraded shares of Davita from a “sell” rating to a “hold” rating in a research report on Monday, July 22nd. Finally, Zacks Investment Research upgraded shares of Davita from a “sell” rating to a “hold” rating in a research report on Friday, May 10th. Eight equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $67.06.
Davita (NYSE:DVA) last released its quarterly earnings data on Thursday, August 1st. The company reported $1.22 EPS for the quarter, beating the Zacks’ consensus estimate of $1.10 by $0.12. The business had revenue of $2.84 billion during the quarter, compared to analysts’ expectations of $2.86 billion. Davita had a net margin of 1.21% and a return on equity of 14.67%. The firm’s quarterly revenue was down 1.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.05 EPS. Equities analysts forecast that Davita Inc will post 4.74 earnings per share for the current year.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Recommended Story: The Discount Rate – What You Need to Know
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davita Inc (NYSE:DVA).
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.